Related Experiment Video

Updated: Mar 12, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment

Cbf Bueno1, E B Trarbach2, M D Bronstein2

  • 1Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas & Laboratory of Cellular and Molecular Endocrinology LIM-25, University of São Paulo Medical School, São Paulo, Brazil. cbformiga@gmail.com.

Pituitary
|November 17, 2016
PubMed
Abstract

Insights

Dopamine receptor gene (DRD2) polymorphisms do not appear to influence cabergoline treatment response in prolactinoma patients. Further research is needed to understand genetic impacts on dopamine agonist effectiveness.

Area of Science:

  • Endocrinology
  • Pharmacogenetics
  • Oncology

Background:

  • Prolactinomas often respond to dopamine agonists (DA), but resistance occurs.
  • Mechanisms of resistance involve dopamine receptor subtype 2 (DRD2) and its isoforms.
  • DRD2 gene polymorphisms may affect cabergoline (CAB) effectiveness.

Purpose of the Study:

  • To investigate the association between DRD2 gene polymorphisms and patient responsiveness to cabergoline treatment for prolactinoma.

Main Methods:

  • A case-control study analyzed DRD2 polymorphisms in 148 prolactinoma patients and 349 controls.
  • Responsiveness to CAB was assessed in 118 patients based on prolactin normalization.
  • Clinical characteristics and genetic variants were evaluated for association with CAB response.

Main Results:

  • No significant differences in DRD2 genotypes or allele frequencies were found between patients and controls.
  • No association was observed between DRD2 polymorphisms and CAB responsiveness in prolactinoma patients.
  • Specific DRD2 polymorphisms (rs1076560 and rs1800497) were associated with the presence of macroadenomas.

Conclusions:

  • DRD2 gene polymorphisms do not correlate with cabergoline treatment responsiveness in prolactinoma.
  • Additional studies are required to determine the role of DRD2 genotyping in dopamine agonist therapy outcomes.
Keywords:
CabergolineDRD2Dopamine agonistPolymorphismProlactinoma

More Related Videos

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.8K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
55
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K